Tevogen Bio Holdings Inc. - Common Stock TVGN 深 滬
等待開盤 08-15 09:30:00 美东时间
0.98
-0.030
-2.97%
華盛通- 最 高1.02
- 今 開1.01
- 成交量 66.37万股
- 最 低 0.9701
- 昨 收 1.01
- 總市值 1.80亿
- 52周最高 3.09
- 市盈率 靜 --
- 換手率 0.36%
- 52周最低 0.2556
- 委 比 92.31%
- 總股本 1.84亿
- 歷史最高 21.09
- 量 比 0.47
- 振 幅 4.94%
- 歷史最低 0.2556
- 每 手 1
- 風險率 2.32%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion
Tevogen Bio Holdings Inc. reaffirms investor confidence and estimates its asset value to exceed $10 billion. HMP Partners and The Patel Family LLP commended the company's efforts in addressing health disparities through medical innovations, highlighting its leadership's achievements and a product pipeline across therapeutic areas. In 2022, Tevogen was valued at $4.2 billion as the highest-valued biotech unicorn. Hema Patel estimated the current m...
08-11 19:45
Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow
Tevogen Bio forecasts $10-14 billion in 5-year oncology revenue, prioritizing cancer patients vulnerable to SARS-CoV-2. TVGN 489 targets COVID-19 and Long COVID in immunocompromised patients, while the pipeline includes treatments for cervical cancer, EBV lymphomas, and multiple sclerosis. The company emphasizes patient accessibility and sustainable innovation.
08-11 15:58
REPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders
<p>Tevogen Bio Holdings Inc. (Nasdaq: TVGN) has rapidly evolved into a dynamic enterprise expanding into artificial intelligence through Tevogen.AI. The company's mission is to deliver clinically impactful, economically accessible therapies by leveraging cutting-edge science and technology. Tevogen emphasizes social responsibility, patient affordability, and cost efficiency. Recent advancements include the successful launch of their proprietary A...
08-11 13:28
Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy
Tevogen Bio Holdings Inc. has received $1 million in funding to advance its Tevogen.AI drug discovery initiative, part of a potential $10 million grant from KRHP LLC. The company is well-capitalized, enabling it to execute its growth strategy. The funding will enhance AI capabilities for faster drug development and improved patient access, following the recent patent publication of its machine learning technology for predicting immunologically ac...
08-07 13:00
Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions
Tevogen reports a 60% increase in institutional ownership of its common stock from December 2024 to March 2025, with Vanguard and BlackRock contributing 151% growth. 73% of 51 institutional holders increased or maintained positions, reflecting significant new investor interest. Tapan Shah highlights confidence in the company's fundamentals and long-term potential, citing advancements in Tevogen.AI, collaborations with Microsoft and Databricks, an...
08-06 19:59
Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology
Tevogen.AI is collaborating with Microsoft and Databricks to develop the beta version of its PredicTcell model, incorporating oncology data to enhance accuracy and diversity. The initiative aims to accelerate cancer immunotherapy development while expanding external market opportunities. Enhanced analytics and visualization tools are being developed to support internal R&D. These efforts build on a recent international patent for novel machine le...
08-05 18:32
Tevogen Bio To Receive $1M Grant To Advance AI-Driven Drug Discovery Platform, Part Of $10M Non-Dilutive Funding From KRHP
Funds will support advancement of Tevogen.AI, the Company's artificial intelligence–driven drug discovery initiative.The $1 million is part of up to $10 million in previously announced non‑dilutive grant funding from
08-02 03:37
Tevogen Bio to Accept $1 Million Additional Grant Funding for AI Expansion
Tevogen Bio Holdings Inc. announced it expects to receive $1 million in grant funding to advance Tevogen.AI, its artificial intelligence-driven drug discovery program. This funding is part of up to $10 million in non-dilutive grants from KRHP LLC. The company plans to use the funds to enhance target discovery, reduce development timelines, and improve treatment accessibility.
08-01 19:30
Tevogen Highlights 74% Insider Ownership, Reinforcing Long-Term Vision
Tevogen, a biopharmaceutical company, announced that its executive officers and board members collectively own over 74% of its outstanding shares. This significant insider ownership reflects their strong belief in the company's mission and long-term strategy. CEO Dr. Ryan Saadi highlighted the team's control over decision-making, enabling continued rapid growth and innovation in developing off-the-shelf T cell therapeutics for infectious diseases...
07-30 16:41
Tevogen.AI Applauds U.S. Government’s AI Action Plan; Reaffirms Commitment to Accelerating AI Innovation in Healthcare
<p>Tevogen Bio Holdings Inc. (Nasdaq: TVGN) welcomes the U.S. government's "AI Action Plan," emphasizing domain-specific standards and healthcare AI innovations. The company highlights its collaboration with Microsoft and Databricks to develop PredicTcell™, a machine learning model that accelerates immunotherapy research and reduces drug development costs. CEO Ryan Saadi stresses AI's potential to lower treatment costs and improve access to healt...
07-28 15:52
